Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
2.350
-0.030 (-1.26%)
At close: Sep 21, 2026, 4:00 PM EDT
2.360
+0.010 (0.43%)
After-hours: Sep 21, 2026, 7:30 PM EDT
Cellectar Biosciences Employees
Cellectar Biosciences had 11 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
11
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,029,427
Market Cap
22.21M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 11 | 0 | - |
| Dec 31, 2024 | 11 | -9 | -45.00% |
| Dec 31, 2023 | 20 | 5 | 33.33% |
| Dec 31, 2022 | 15 | 3 | 25.00% |
| Dec 31, 2021 | 12 | 1 | 9.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 138 |
| Jasper Therapeutics | 22 |
| Atossa Therapeutics | 16 |
| Tvardi Therapeutics | 12 |
| Actuate Therapeutics | 12 |
| Psyence Biomedical | 12 |
| Cocrystal Pharma | 10 |
| Polyrizon | 4 |
CLRB News
- 4 weeks ago - Cellectar Biosciences Transcript: Study update - Transcripts
- 4 weeks ago - Cellectar Biosciences Slides: Study update - Filings
- 4 weeks ago - Cellectar Biosciences Slides: Corporate presentation - Filings
- 5 weeks ago - Cellectar Biosciences reports Q2 EPS (57c), consensus (52c) - TheFly
- 5 weeks ago - Cellectar Biosciences Earnings Call Transcript: Q2 2026 - Transcripts
- 5 weeks ago - Cellectar Biosciences Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Cellectar Biosciences Earnings release: Q2 2026 - Filings
- 5 weeks ago - Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewsWire